Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection

Mascia, Claudia; Lichtner, Miriam; Zuccalà, Paola; Vita, Serena; Tieghi, Tiziana; Marocco, Raffaella; Savinelli, Stefano; Rossi, Roberto; Iannetta, Marco; Campagna, Michela; Schiavone, Francesco; Mengoni, Fabio; Russo, Gianluca; Mastroianni, Claudio Maria; Vullo, Vincenzo

doi:10.1016/j.clinre.2017.04.007

Cited by 25 publications

(28 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…infected patients have reported similar results to studies in HCV mono-infected patients ( Table 4 and Table S4) Studies have demonstrated elevated levels of sVCAM-1, 137,145 sICAM-1, 137,[145][146][147] sCD14, 138,148 sCD163, [148][149][150] sP-selectin, and sE-selectin 147,151 among co-infected patients, which correlated with disease progression 145 and treatment response, 145 decreased with therapy, 145,147 predicted liver related mortality 143 and were significantly associated with subclinical cardiovascular disease. 148 Finally, one study reported significantly elevated BNP elevated levels among HIV/HCV coinfected patients compared to HIV mono-infected patients.…”

Section: Studies Of Markers Of Endothelial Function In Hiv/hcv Co-supporting

confidence: 77%

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review

Babiker

Hassan

Muhammed

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infects 180 million people worldwide and over 4 million people in the United States. HCV infection is a major cause of chronic liver disease and is recognized as a risk factor for clinical cardiovascular disease (CVD). Many studies have shown increased prevalence of cardiac and inflammatory biomarkers in patients with chronic HCV infection (CHC), and though these markers may be used to risk stratify people for cardiac disease in the general population their role in the HCV population is unknown. Patients with CHC have elevated cardiac and inflammatory biomarkers compared to noninfected controls which may play a role in CVD risk stratification. We undertook a systematic review of inflammatory and cardiac biomarkers in people with HCV infection with a focus on the effect of CHC on serum levels of these markers and their utility as predictors of CVD in this population. Medline, EMBASE, and Cochrane databases were searched for relevant articles until June 2019. A total of 2430 results were reviewed with 115 studies included. Our review revealed that HCV infection significantly alters serum levels of markers of inflammation, endothelial function, and cardiac dysfunction prior to HCV treatment, and some of which may change in response to HCV therapy. Current risk stratification tools for development of CVD in the general population may not account for the increased inflammatory markers that appear to be elevated among HCV‐infected patients contributing to increased CVD risk.

show abstract

Section: Studies Of Markers Of Endothelial Function In Hiv/hcv Co-supporting

confidence: 77%

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review

Babiker

Hassan

Muhammed

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…These biomarkers tend not to normalize in ART‐treated PLWH, suggesting that viral replication is not the primary driver of chronic inflammation in PLWH (Marchetti et al., ). Coinfection with HIV and hepatitis C virus (HCV) leads to greater elevation in sCD163 than HIV monoinfection, consistent with the role of sCD163 in hepatic inflammation (Lidofsky et al., ; Mascia et al., ; Shmagel et al., ). Clinical utility of these biomarkers, particularly sCD14 and sCD163, derives from their ability to predict cognitive impairment, morbidity, and all‐cause mortality in PLWH, independent of clinical factors (Ancuta et al., ; Burdo et al., ; Hunt et al., ; Imp et al., ; Knudsen et al., ; Monnig et al., ; Royal et al., ; Sandler et al., ).…”

mentioning

confidence: 58%

HIV Infection, HCV Coinfection, and Alcohol Use: Associations with Microbial Translocation and Immune Activation

Monnig

Cohen

Ramratnam

et al. 2019

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

Background: Human immunodeficiency virus (HIV) infection and heavy drinking independently promote microbial translocation and inflammation. However, it is not known how alcohol use may affect these processes in people living with HIV (PLWH). This study tested the hypothesis that alcohol exacerbates innate immune dysfunction in PLWH.Methods: Participants were 75 PLWH and 34 uninfected controls. Groups were recruited to have similar proportions of nondrinkers, moderate drinkers, and heavy drinkers. Substance use data and plasma samples were collected at up to 3 visits over a 5-year study period. Recent alcohol use was assessed with the Timeline Followback Interview. Biomarkers of microbial translocation (lipopolysaccharide, LPS) and immune activation (lipopolysaccharide binding protein, LBP; soluble CD14, sCD14; soluble CD163, sCD163) were quantified using enzyme-linked immunosorbent assays. Analyses tested 2 hypotheses: (i) that biomarker levels would be significantly higher in PLWH than controls with comparable alcohol use and (ii) that current alcohol use would exacerbate biomarker elevations in PLWH. The second analysis included the interaction of alcohol use with hepatitis C virus (HCV) coinfection.Results: Groups were matched on alcohol use, smoking, and other drug use. All biomarkers were significantly higher in PLWH relative to controls (LBP: p = 0.005; LPS: p = 0.014; sCD14: p < 0.001; sCD163: p < 0.001). In PLWH, alcohol use showed a significant, positive association with sCD163, but not with other biomarkers. However, the interaction of alcohol use with HCV coinfection was significant for all biomarkers (LBP: p = 0.002; LPS: p = 0.026; sCD14: p = 0.0004; sCD163: p = 0.001). In pairwise tests with sequential Bonferroni correction, HIV/HCV coinfected individuals who drank heavily had significantly higher sCD163 compared to coinfected nondrinkers and to HIV monoinfected nondrinkers, moderate drinkers, and heavy drinkers (ps < 0.005). Coinfected moderate drinkers had significantly higher sCD163 than each monoinfected group (ps < 0.003). In addition, sCD14 was significantly higher in coinfected moderate drinkers than coinfected nondrinkers (p = 0.027).Conclusions: As predicted, PLWH had higher levels of LBP, LPS, sCD14, and sCD163 than uninfected individuals with similar alcohol use. In PLWH, alcohol by itself was significantly associated only with higher sCD163. However, heavy or moderate alcohol use was associated with elevations in macrophage activation (sCD163) and monocyte activation (sCD14) in HIV/HCV coinfected individuals.

show abstract

“…Several unique studies have provided the means for a non‐invasive screening of liver fibrosis in HIV/HCV coinfection, using the macrophage activation marker soluble CD163 or surface‐enhanced laser desorption ionization time‐of‐flight mass spectrometry . In the present study we focused on WFA + ‐M2BP, which has multibranching and sialylated N‐glycans, and is well known as a marker of liver fibrosis for use in various types of liver disease, including hepatitis B, hepatitis C, and non‐alcoholic fatty liver disease .…”

Section: Discussionmentioning

confidence: 99%

Wisteria floribunda agglutinin‐positive human Mac‐2‐binding protein as a predictive marker of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients

Takatsuki

Yamasaki

Natsuda

et al. 2020

Hepatology Research

View full text Add to dashboard Cite

Aim: In human immunodeficiency virus (HIV) and hepatitis C virus (HCV) coinfected patients, the progression of liver failure is reported to be more aggressive than that in HCV monoinfected patients. Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA + -M2BP) is well recognized as a liver fibrosis glycobiomarker with a unique fibrosis-related glycoalteration. We analyzed HIV/HCV coinfected patients' M2BP levels as a possible marker for predicting liver fibrosis.Methods: M2BP was measured in 31 HIV/HCV coinfected patients, and we analyzed the correlation between WFA + -M2BP and several markers of fibrosis, liver function, and tumor markers. We compared the WFA + -M2BP levels in HIV/HCV coinfected patients with those of HCV mono-infected patients by performing a propensity score matching analysis.Results: In the HIV/HCV coinfected patients, the serum level of WFA + -M2BP was well correlated with the markers type IV collagen, hyaluronic acid, and alpha-fetoprotein, but not protein induced by vitamin K absence-II. In the propensity score matching with HCV mono-infected patients, the WFA + -M2BP levels were significantly higher in the HIV/HCV coinfected patients compared with the levels in the HCV mono-infected patients. Conclusion:In conclusion, WFA + -M2BP might be a feasible predictive marker of fibrosis in HIV/HCV coinfected patients.

show abstract

Active HCV infection is associated with increased circulating levels of interferon-gamma (IFN-γ)-inducible protein-10 (IP-10), soluble CD163 and inflammatory monocytes regardless of liver fibrosis and HIV coinfection

Cited by 25 publications

References 50 publications

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review

Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review

HIV Infection, HCV Coinfection, and Alcohol Use: Associations with Microbial Translocation and Immune Activation

Wisteria floribunda agglutinin‐positive human Mac‐2‐binding protein as a predictive marker of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients

Contact Info

Product

Resources

About